We serve Chemical Name:1-Bromo-2-chloro-4-ethoxy-3-fluorobenzene CAS:909122-17-4 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:1-Bromo-2-chloro-4-ethoxy-3-fluorobenzene
CAS.NO:909122-17-4
Synonyms:1-Bromo-2-chloro-4-ethoxy-3-fluorobenzene
Molecular Formula:C8H7BrClFO
Molecular Weight:253.49600
HS Code:
Physical and Chemical Properties:
Melting point:48-49ºC
Boiling point:277ºC
Density:1.562
Index of Refraction:
PSA:9.23000
Exact Mass:251.93500
LogP:3.64030
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 1-Bromo-2-chloro-4-ethoxy-3-fluorobenzene chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,1-Bromo-2-chloro-4-ethoxy-3-fluorobenzene physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,1-Bromo-2-chloro-4-ethoxy-3-fluorobenzene Use and application,1-Bromo-2-chloro-4-ethoxy-3-fluorobenzene technical grade,usp/ep/jp grade.
Related News: As many as 9,000 medical workers in Hong Kong have pledged to strike this week, a threat that alarms the territory��s officials as they are struggling to contain the coronavirus outbreak. 1-Bromo-2-chloro-4-ethoxy-3-fluorobenzene manufacturer It does not require a production license for the drug substance, and can be produced in an ordinary chemical plant. As long as it reaches a certain level, it can be used for the synthesis of the drug substance. 1-Bromo-2-chloro-4-ethoxy-3-fluorobenzene supplier It does not require a production license for the drug substance, and can be produced in an ordinary chemical plant. As long as it reaches a certain level, it can be used for the synthesis of the drug substance. 1-Bromo-2-chloro-4-ethoxy-3-fluorobenzene vendor This time frame optimizes the opportunity to respond to treatment with an HMA prior to declaring treatment failure, as per NCCN Guidelines. Patients are randomized at a 2:1 ratio into two study arms: IV rigosertib plus Best Supportive Care versus Physician��s Choice plus Best Supportive Care. 1-Bromo-2-chloro-4-ethoxy-3-fluorobenzene factory This time frame optimizes the opportunity to respond to treatment with an HMA prior to declaring treatment failure, as per NCCN Guidelines. Patients are randomized at a 2:1 ratio into two study arms: IV rigosertib plus Best Supportive Care versus Physician��s Choice plus Best Supportive Care.
